ZBH

SEC source: 0001062993-22-008198 · form4.xml · nonDerivative · entry 4

Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,539

F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person on March 9, 2022.

F5 · price: Reflects the weighted average price of 5,331 shares of common stock of Zimmer Biomet Holdings, Inc. sold in multiple transactions on March 17, 2022 with sale prices ranging from $122.37 to $122.57 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuance, full information regarding the number of shares sold at each separate price.

SEC source: 0001062993-22-008198 · form4.xml · nonDerivative · entry 3

Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,870

F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person on March 9, 2022.

F4 · price: Reflects the weighted average price of 29,518 shares of common stock of Zimmer Biomet Holdings, Inc. sold in multiple transactions on March 17, 2022 with sale prices ranging from $121.37 to $122.365 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuance, full information regarding the number of shares sold at each separate price.

SEC source: 0001062993-22-008198 · form4.xml · nonDerivative · entry 2

Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,388

F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person on March 9, 2022.

F3 · price: Reflects the weighted average price of 300 shares of common stock of Zimmer Biomet Holdings, Inc. sold in multiple transactions on March 17, 2022 with sale prices ranging from $120.29 to $120.90 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuance, full information regarding the number of shares sold at each separate price.

SEC source: 0001062993-22-008198 · form4.xml · nonDerivative · entry 1

Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,688

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person on March 9, 2022.

F2 · balance_after: Includes 387 shares acquired under the Zimmer Biomet Holdings, Inc. Employee Stock Purchase Plan and pursuant to dividend reinvestment between April 28, 2021 and January 27, 2022.

SEC source: 0001062993-22-007442 · form4.xml · nonDerivative · entry 1

Winkler Lori · CIK 0001852191 · SVP and CHRO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 231

F1 · shares: Represents shares withheld by Zimmer Biomet Holdings, Inc. (the "Company") to satisfy tax withholding obligations on the vesting of restricted stock units.

F2 · balance_after: Holdings reflect the adjustments that occurred as of March 1, 2022 in connection with the Company's spinoff of ZimVie Inc. On March 4, 2022, the reporting person reported the acquisition of 181 shares upon the vesting of restricted stock units on March 2, 2022, which did not yet reflect certain adjustments made to outstanding equity awards effective March 1, 2022 in connection with the spinoff to preserve the intrinsic value of such awards, because the exchange ratio to be used for such adjustments had not yet been determined. Subsequently, the exchange ratio calculation was completed, and the 181 shares were adjusted to 187 shares, which is now reflected in the reporting person's total holdings.

SEC source: 0001062993-22-006834 · form4.xml · derivative · entry 2

Winkler Lori · CIK 0001852191 · SVP and CHRO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 362

Underlying: Common Stock · 181 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

F3 · derivative.exercise_date: The RSUs vest in equal portions on each of March 2, 2022, March 2, 2023 and March 2, 2024.

F3 · derivative.expiration_date: The RSUs vest in equal portions on each of March 2, 2022, March 2, 2023 and March 2, 2024.

SEC source: 0001062993-22-006834 · form4.xml · nonDerivative · entry 1

Winkler Lori · CIK 0001852191 · SVP and CHRO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 290

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 1 share acquired pursuant to dividend reinvestment between April 28, 2021 and January 27, 2022.

SEC source: 0001062993-22-006634 · form4.xml · derivative · entry 2

Upadhyay Suketu · CIK 0001533149 · Exec. VP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,831

Underlying: Common Stock · 6,831 shares

Expires 2024-02-25

F1 · derivative.exercise_price: (1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock.

F2 · shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

F2 · derivative.underlying_shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

F2 · balance_after: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

SEC source: 0001062993-22-006634 · form4.xml · derivative · entry 1

Upadhyay Suketu · CIK 0001533149 · Exec. VP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,744

Underlying: Common Stock · 3,744 shares

Expires 2023-02-21

F1 · derivative.exercise_price: (1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock.

F2 · shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

F2 · derivative.underlying_shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

F2 · balance_after: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

SEC source: 0001062993-22-006630 · form4.xml · derivative · entry 3

Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,641

Underlying: Common Stock · 1,641 shares

Expires 2024-03-01

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock.

SEC source: 0001062993-22-006630 · form4.xml · derivative · entry 2

Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,442

Underlying: Common Stock · 4,442 shares

Expires 2024-02-25

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock.

F2 · shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

F2 · derivative.underlying_shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

F2 · balance_after: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

SEC source: 0001062993-22-006630 · form4.xml · derivative · entry 1

Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,129

Underlying: Common Stock · 2,129 shares

Expires 2023-02-21

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock.

F2 · shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

F2 · derivative.underlying_shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

F2 · balance_after: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

SEC source: 0001062993-22-006637 · form4.xml · derivative · entry 3

Yi Sang · CIK 0001635943 · President, Asia Pacific

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,052

Underlying: Common Stock · 2,052 shares

Expires 2024-03-01

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock.

SEC source: 0001062993-22-006637 · form4.xml · derivative · entry 2

Yi Sang · CIK 0001635943 · President, Asia Pacific

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,895

Underlying: Common Stock · 4,895 shares

Expires 2024-02-25

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock.

F2 · shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

F2 · derivative.underlying_shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

F2 · balance_after: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

SEC source: 0001062993-22-006637 · form4.xml · derivative · entry 1

Yi Sang · CIK 0001635943 · President, Asia Pacific

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,350

Underlying: Common Stock · 2,350 shares

Expires 2023-02-21

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock.

F2 · shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

F2 · derivative.underlying_shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

F2 · balance_after: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

SEC source: 0001062993-22-006636 · form4.xml · derivative · entry 2

Winkler Lori · CIK 0001852191 · SVP and CHRO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 748

Underlying: Common Stock · 748 shares

Expires 2024-04-01

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock.

F2 · derivative.underlying_shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, as indicated in the table above. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

F2 · balance_after: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, as indicated in the table above. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

SEC source: 0001062993-22-006636 · form4.xml · derivative · entry 1

Winkler Lori · CIK 0001852191 · SVP and CHRO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,254

Underlying: Common Stock · 1,254 shares

Expires 2024-02-25

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock.

F2 · derivative.underlying_shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, as indicated in the table above. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

F2 · balance_after: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, as indicated in the table above. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

SEC source: 0001062993-22-006633 · form4.xml · derivative · entry 2

Tornos Ivan · CIK 0001757216 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,287

Underlying: Common Stock · 7,287 shares

Expires 2024-02-25

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock.

F2 · shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

F2 · derivative.underlying_shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

F2 · balance_after: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

SEC source: 0001062993-22-006633 · form4.xml · derivative · entry 1

Tornos Ivan · CIK 0001757216 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,891

Underlying: Common Stock · 3,891 shares

Expires 2023-02-21

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock.

F2 · shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

F2 · derivative.underlying_shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

F2 · balance_after: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

SEC source: 0001062993-22-006629 · form4.xml · derivative · entry 2

Ellingson Rachel · CIK 0001557271 · SVP & Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,708

Underlying: Common Stock · 1,708 shares

Expires 2024-02-25

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock.

F2 · shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

F2 · derivative.underlying_shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

F2 · balance_after: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

SEC source: 0001062993-22-006629 · form4.xml · derivative · entry 1

Ellingson Rachel · CIK 0001557271 · SVP & Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,014

Underlying: Common Stock · 1,014 shares

Expires 2023-02-21

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock.

F2 · shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

F2 · derivative.underlying_shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

F2 · balance_after: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

SEC source: 0001062993-22-006627 · form4.xml · derivative · entry 2

Hanson Bryan C · CIK 0001524349 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,524

Underlying: Common Stock · 26,524 shares

Expires 2024-02-25

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock.

F2 · shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

F2 · derivative.underlying_shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

F2 · balance_after: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

SEC source: 0001062993-22-006627 · form4.xml · derivative · entry 1

Hanson Bryan C · CIK 0001524349 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,680

Underlying: Common Stock · 14,680 shares

Expires 2023-02-21

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock.

F2 · shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

F2 · derivative.underlying_shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

F2 · balance_after: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

SEC source: 0001062993-22-006628 · form4.xml · derivative · entry 2

Davis Derek M · CIK 0001399228 · Interim Controller & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,026

Underlying: Common Stock · 1,026 shares

Expires 2024-02-25

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock.

F2 · shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

F2 · derivative.underlying_shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

F2 · balance_after: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

SEC source: 0001062993-22-006628 · form4.xml · derivative · entry 1

Davis Derek M · CIK 0001399228 · Interim Controller & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 661

Underlying: Common Stock · 661 shares

Expires 2023-02-21

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock.

F2 · shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

F2 · derivative.underlying_shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

F2 · balance_after: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed.

SEC source: 0001062993-22-005371 · form4.xml · derivative · entry 1

Winkler Lori · CIK 0001852191 · SVP and CHRO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,682

Underlying: Common Stock · 16,682 shares

Expires 2032-02-18

F1 · derivative.exercise_date: Vests annually over three years in increments of one-third each year, commencing on February 18, 2023.

SEC source: 0001062993-22-005362 · form4.xml · derivative · entry 1

Davis Derek M · CIK 0001399228 · Interim Controller & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,583

Underlying: Common Stock · 7,583 shares

Expires 2032-02-18

F1 · derivative.exercise_date: Vests annually over three years in increments of one-third each year, commencing on February 18, 2023.

SEC source: 0001062993-22-005368 · form4.xml · derivative · entry 1

Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,507

Underlying: Common Stock · 23,507 shares

Expires 2032-02-18

F1 · derivative.exercise_date: Vests annually over three years in increments of one-third each year, commencing on February 18, 2023.

SEC source: 0001062993-22-005364 · form4.xml · derivative · entry 1

Ellingson Rachel · CIK 0001557271 · SVP & Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,891

Underlying: Common Stock · 12,891 shares

Expires 2032-02-18

F1 · derivative.exercise_date: Vests annually over three years in increments of one-third each year, commencing on February 18, 2023.

SEC source: 0001062993-22-005361 · form4.xml · derivative · entry 1

Yi Sang · CIK 0001635943 · President, Asia Pacific

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,782

Underlying: Common Stock · 25,782 shares

Expires 2032-02-18

F1 · derivative.exercise_date: Vests annually over three years in increments of one-third each year, commencing on February 18, 2023.

SEC source: 0001062993-22-005347 · form4.xml · derivative · entry 1

Tornos Ivan · CIK 0001757216 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,903

Underlying: Common Stock · 59,903 shares

Expires 2032-02-18

F1 · derivative.exercise_date: Vests annually over three years in increments of one-third each year, commencing on February 18, 2023.

SEC source: 0001062993-22-005356 · form4.xml · derivative · entry 1

Hanson Bryan C · CIK 0001524349 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 166,819

Underlying: Common Stock · 166,819 shares

Expires 2032-02-18

F1 · derivative.exercise_date: Vests annually over three years in increments of one-third each year, commencing on February 18, 2023.

SEC source: 0001062993-22-005350 · form4.xml · derivative · entry 1

VAN ZUILEN WILFRED · CIK 0001864818 · Pres, Europe, M. East & Africa

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,232

Underlying: Common Stock · 21,232 shares

Expires 2032-02-18

F1 · derivative.exercise_date: Vests annually over three years in increments of one-third each year, commencing on February 18, 2023.

SEC source: 0001062993-22-005351 · form4.xml · derivative · entry 1

Upadhyay Suketu · CIK 0001533149 · Exec. VP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,046

Underlying: Common Stock · 50,046 shares

Expires 2032-02-18

F1 · derivative.exercise_date: Vests annually over three years in increments of one-third each year, commencing on February 18, 2023.

SEC source: 0001062993-22-000634 · form4.xml · derivative · entry 1

Davis Derek M · CIK 0001399228 · Interim Controller & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 830

Underlying: Common Stock · 830 shares

Expires 2023-12-01

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock.

SEC source: 0001062993-22-000391 · form4.xml · derivative · entry 1

Kolli Sreelakshmi · CIK 0001689392 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 872.56

Underlying: Common Stock · 107.397 shares

Expires not disclosed

F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1.

F3 · derivative.exercise_date: Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.

F3 · derivative.expiration_date: Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.

F4 · balance_after: Includes 1.297 phantom stock units accrued on October 29, 2021 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

SEC source: 0001062993-22-000389 · form4.xml · derivative · entry 1

HAGEMANN ROBERT · CIK 0001222676 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,853.928

Underlying: Common Stock · 263.61 shares

Expires not disclosed

F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1.

F3 · derivative.exercise_date: Units are to be settled in cash in five annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs.

F3 · derivative.expiration_date: Units are to be settled in cash in five annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs.

F4 · balance_after: Includes 38.286 phantom stock units accrued on October 29, 2021 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

SEC source: 0001062993-22-000366 · form4.xml · derivative · entry 1

Hilado Maria Teresa · CIK 0001587868 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,336.788

Underlying: Common Stock · 214.794 shares

Expires not disclosed

F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1.

F3 · derivative.exercise_date: 107.397 of the units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. The remaining units are to be settled in cash in four annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs.

F3 · derivative.expiration_date: 107.397 of the units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. The remaining units are to be settled in cash in four annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs.

F4 · balance_after: Includes 6.986 phantom stock units accrued on October 29, 2021 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

SEC source: 0001062993-22-000354 · form4.xml · derivative · entry 1

Farrell Michael J. · CIK 0001485164 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,766.969

Underlying: Common Stock · 244.083 shares

Expires not disclosed

F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1.

F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director.

F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director.

F4 · balance_after: Includes 16.139 phantom stock units accrued on October 29, 2021 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

SEC source: 0001062993-22-000352 · form4.xml · derivative · entry 1

Jafry Syed A. · CIK 0001745891 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,925.837

Underlying: Common Stock · 107.397 shares

Expires not disclosed

F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1.

F3 · derivative.exercise_date: Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.

F3 · derivative.expiration_date: Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.

F4 · balance_after: Includes 4.777 phantom stock units accrued on October 29, 2021 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

SEC source: 0001062993-22-000331 · form4.xml · derivative · entry 1

BEGLEY CHRISTOPHER B · CIK 0001239420 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,906.398

Underlying: Common Stock · 292.9 shares

Expires not disclosed

F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1.

F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director.

F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director.

F4 · balance_after: Includes 23.072 phantom stock units accrued on October 29, 2021 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

SEC source: 0001062993-22-000344 · form4.xml · derivative · entry 1

HIGGINS ARTHUR J · CIK 0001142083 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,450.043

Underlying: Common Stock · 253.846 shares

Expires not disclosed

F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1.

F3 · derivative.exercise_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs.

F3 · derivative.expiration_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs.

F4 · balance_after: Includes 46.092 phantom stock units accrued on October 29, 2021 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

SEC source: 0001062993-22-000330 · form4.xml · derivative · entry 1

MICHELSON MICHAEL W · CIK 0001182415 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,733.742

Underlying: Common Stock · 214.793 shares

Expires not disclosed

F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1.

F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director.

F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director.

F4 · balance_after: Includes 14.438 phantom stock units accrued on October 29, 2021 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

SEC source: 0001062993-22-000321 · form4.xml · derivative · entry 1

BERNARD BETSY J · CIK 0001166854 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,012.346

Underlying: Common Stock · 244.083 shares

Expires not disclosed

F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1.

F3 · derivative.exercise_date: Units are to be settled in cash in four annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs.

F3 · derivative.expiration_date: Units are to be settled in cash in four annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs.

F4 · balance_after: Includes 25.029 phantom stock units accrued on October 29, 2021 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

SEC source: 0001062993-21-013313 · form4.xml · derivative · entry 6

Hanson Bryan C · CIK 0001524349 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 32,950 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each PRSU represents a contingent right to receive one share of Company common stock.

F4 · shares: On December 19, 2017, the reporting person was granted 49,425 PRSUs, which were to be earned if and to the extent certain stock price performance goals were achieved by December 19, 2021. The Company's compensation committee determined that, based on actual stock price performance, 32,950 PRSUs were earned and vested on December 19, 2021. The remaining 16,475 PRSUs were forfeited.

F4 · derivative.exercise_date: On December 19, 2017, the reporting person was granted 49,425 PRSUs, which were to be earned if and to the extent certain stock price performance goals were achieved by December 19, 2021. The Company's compensation committee determined that, based on actual stock price performance, 32,950 PRSUs were earned and vested on December 19, 2021. The remaining 16,475 PRSUs were forfeited.

F4 · derivative.expiration_date: On December 19, 2017, the reporting person was granted 49,425 PRSUs, which were to be earned if and to the extent certain stock price performance goals were achieved by December 19, 2021. The Company's compensation committee determined that, based on actual stock price performance, 32,950 PRSUs were earned and vested on December 19, 2021. The remaining 16,475 PRSUs were forfeited.

SEC source: 0001062993-21-013313 · form4.xml · derivative · entry 5

Hanson Bryan C · CIK 0001524349 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,520 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each PRSU represents a contingent right to receive one share of Company common stock.

F1 · shares: On December 19, 2017, the reporting person was granted 38,280 performance restricted stock units ("PRSUs"), which were to be earned if and to the extent certain stock price performance goals were achieved by December 19, 2021. The Company's compensation committee determined that, based on actual stock price performance, 25,520 PRSUs were earned and vested on December 19, 2021. The remaining 12,760 PRSUs were forfeited.

F1 · derivative.exercise_date: On December 19, 2017, the reporting person was granted 38,280 performance restricted stock units ("PRSUs"), which were to be earned if and to the extent certain stock price performance goals were achieved by December 19, 2021. The Company's compensation committee determined that, based on actual stock price performance, 25,520 PRSUs were earned and vested on December 19, 2021. The remaining 12,760 PRSUs were forfeited.

F1 · derivative.expiration_date: On December 19, 2017, the reporting person was granted 38,280 performance restricted stock units ("PRSUs"), which were to be earned if and to the extent certain stock price performance goals were achieved by December 19, 2021. The Company's compensation committee determined that, based on actual stock price performance, 25,520 PRSUs were earned and vested on December 19, 2021. The remaining 12,760 PRSUs were forfeited.

SEC source: 0001062993-21-013313 · form4.xml · nonDerivative · entry 4

Hanson Bryan C · CIK 0001524349 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,223

F3 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations on the vesting of PRSUs.

SEC source: 0001062993-21-013313 · form4.xml · nonDerivative · entry 3

Hanson Bryan C · CIK 0001524349 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,493

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · shares: On December 19, 2017, the reporting person was granted 49,425 PRSUs, which were to be earned if and to the extent certain stock price performance goals were achieved by December 19, 2021. The Company's compensation committee determined that, based on actual stock price performance, 32,950 PRSUs were earned and vested on December 19, 2021. The remaining 16,475 PRSUs were forfeited.

SEC source: 0001062993-21-013313 · form4.xml · nonDerivative · entry 2

Hanson Bryan C · CIK 0001524349 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,543

F3 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations on the vesting of PRSUs.

SEC source: 0001062993-21-013313 · form4.xml · nonDerivative · entry 1

Hanson Bryan C · CIK 0001524349 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,369

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On December 19, 2017, the reporting person was granted 38,280 performance restricted stock units ("PRSUs"), which were to be earned if and to the extent certain stock price performance goals were achieved by December 19, 2021. The Company's compensation committee determined that, based on actual stock price performance, 25,520 PRSUs were earned and vested on December 19, 2021. The remaining 12,760 PRSUs were forfeited.

F2 · balance_after: Includes 163 shares acquired under the Zimmer Biomet Holdings, Inc. Employee Stock Purchase Plan on June 30, 2021.